Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Local and Systemic Safety and Tolerability of Ascending Doses of TOP-N53, a Nitric Oxide (NO)-Releasing Phosphodiesterase-5 (PDE5) Inhibitor, Administered Topically, on Wounds in Patients With Digital Ulcers (DU) in Systemic Sclerosis (SSc) in an Open-label, Vehicle-controlled, Phase 2a, Multi-center Clinical Trial

NCT06954597 is registered in ClinicalTrials.gov with Topadur Pharma AG as lead sponsor.

NCT NCT06954597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06954597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Local and Systemic Safety and Tolerability of Ascending Doses of TOP-N53, a Nitric Oxide (NO)-Releasing Phosphodiesterase-5 (PDE5) Inhibitor, Administered Topically, on Wounds in Patients With Digital Ulcers (DU) in Systemic Sclerosis (SSc) in an Open-label, Vehicle-controlled, Phase 2a, Multi-center Clinical Trial
Lead sponsor
Topadur Pharma AG
Phase
Phase 2
Overall status
Recruiting
Start date
February 4, 2025
Completion date
October 31, 2026
Enrollment
15 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

digital ulcers in systemic sclerosis